| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3284069 | Clinical Gastroenterology and Hepatology | 2010 | 10 Pages |
Abstract
Response to open-label induction therapy with certolizumab pegol was achieved by 62% of patients with moderate to severely active Crohn's disease and secondary failure to infliximab. Among these patients, certolizumab pegol 400 mg every 4 weeks showed similar efficacy to every-2-weeks dosing for maintenance of response and remission.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
William J. Sandborn, Maria T. Abreu, Geert D'Haens, Jean-Frédéric Colombel, Severine Vermeire, Krassimir Mitchev, Corinne Jamoul, Richard N. Fedorak, Martina E. Spehlmann, Douglas C. Wolf, Scott Lee, Paul Rutgeerts,